S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:ALBO

Albireo Pharma - ALBO Stock Forecast, Price & News

$44.15
-0.10 (-0.23%)
(As of 03/2/2023)
Add
Compare
Today's Range
$43.99
$44.90
50-Day Range
$43.50
$44.95
52-Week Range
$16.02
$45.23
Volume
1.24 million shs
Average Volume
704,539 shs
Market Capitalization
$913.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.00

Albireo Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
8.7% Upside
$48.00 Price Target
Short Interest
Healthy
2.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.69
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$178,670 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.86) to ($6.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

717th out of 1,005 stocks

Pharmaceutical Preparations Industry

348th out of 486 stocks


ALBO stock logo

About Albireo Pharma (NASDAQ:ALBO) Stock

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
ALBO Albireo Pharma, Inc.
Albireo Pharma, Inc. (ALBO)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
ALBO.PH - | Stock Price & Latest News | Reuters
Why These Two Biotech Stocks Blasted Higher This Week
Expert Ratings for Albireo Pharma
See More Headlines
Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Company Calendar

Last Earnings
11/04/2021
Today
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALBO
Employees
130
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$48.00
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+8.7%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-34,030,000.00
Net Margins
-228.51%
Pretax Margin
-235.11%

Debt

Sales & Book Value

Annual Sales
$40.58 million
Book Value
$9.11 per share

Miscellaneous

Free Float
19,273,000
Market Cap
$913.91 million
Optionable
Optionable
Beta
1.03

Social Links


Key Executives

  • Ronald H. W. Cooper
    President, Chief Executive Officer & Director
  • Simon John HarfordSimon John Harford
    Chief Financial Officer & Treasurer
  • Jan Peter Mattsson
    Chief Scientific Officer, Managing Director-Sweden
  • Joan Connolly
    Chief Technology Officer
  • Paul D. Streck
    Chief Medical Officer













ALBO Stock - Frequently Asked Questions

Should I buy or sell Albireo Pharma stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALBO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALBO, but not buy additional shares or sell existing shares.
View ALBO analyst ratings
or view top-rated stocks.

What is Albireo Pharma's stock price forecast for 2023?

7 brokers have issued twelve-month target prices for Albireo Pharma's shares. Their ALBO share price forecasts range from $42.00 to $59.00. On average, they expect the company's stock price to reach $48.00 in the next twelve months. This suggests a possible upside of 8.7% from the stock's current price.
View analysts price targets for ALBO
or view top-rated stocks among Wall Street analysts.

How have ALBO shares performed in 2023?

Albireo Pharma's stock was trading at $21.61 at the beginning of the year. Since then, ALBO shares have increased by 104.3% and is now trading at $44.15.
View the best growth stocks for 2023 here
.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $3.28. The biopharmaceutical company earned $3.66 million during the quarter, compared to analysts' expectations of $22.33 million. Albireo Pharma had a negative trailing twelve-month return on equity of 97.13% and a negative net margin of 228.51%. During the same period in the previous year, the company earned ($1.96) earnings per share.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Chicago Capital LLC (6.58%), Franklin Resources Inc. (4.47%), ArrowMark Colorado Holdings LLC (3.80%), GW&K Investment Management LLC (3.07%), Rice Hall James & Associates LLC (2.48%) and Sphera Funds Management LTD. (2.24%). Insiders that own company stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends
.

How do I buy shares of Albireo Pharma?

Shares of ALBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $44.15.

How much money does Albireo Pharma make?

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $913.91 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis.

How many employees does Albireo Pharma have?

The company employs 130 workers across the globe.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.

This page (NASDAQ:ALBO) was last updated on 3/27/2023 by MarketBeat.com Staff